UNSPSC 51282902: Alatrofloxacin

This classification denotes a quinolone antibiotic and antimicrobial solution with the molecular formula C26H25F3N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7QVV6I50DT, chemically known as l-alaninamide, l-alanyl-n-(3-(6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthyridin-2-yl)-3-azabicyclo(3.1.0)hex-6-yl)-, (1alpha,5alpha,6alpha)- but generally known as alatrofloxacin, which bears US NIH Compound Identifier 3086677. Alatrofloxacin most often comes in base and mesylate forms.

UNSPSC 51282902 Alatrofloxacin is a Commodity code, but the recent state and local opportunities tagged under it do not reflect purchases of alatrofloxacin (a fluoroquinolone antibiotic) or related single-drug pharmaceuticals. Instead, the code shows minimal relevant activity; the opportunities posted under it span naloxone procurement, broad-based RFIs on direct-to-manufacturer prescription programs, medical and first aid supply bidding for fire rescue operations, and multi-state cooperative purchasing of generic pharmaceuticals and OTC products. The mismatch between the code's nominal scope and actual buying patterns suggests either tagging errors in the source data or that alatrofloxacin itself does not drive material state and local procurement activity on its own.

Geographic activity appears scattered across Florida (Seminole County naloxone bidding), Texas (HHS Commission RFI on pharmacy initiatives), Florida again (Tampa Fire Department medical supplies), and a multi-state cooperative (Minnesota MMCAP serving participating jurisdictions including Oregon). Recent representative solicitations include Seminole County's IFB 60459723LAS (Naloxone & Drug Deactivation Systems, due July 26, 2023, seeking 1,900 units of naloxone annually), the City of Tampa's ITB 26P00145 (Medical and First Aid Supplies for fire rescue, due March 13, 2026, estimated at $700,000 with SLBE set-aside and 5% discount), and the Minnesota MMCAP RFP S1070000015802 (generic multi-source pharmaceuticals and OTC products across state and local facilities, due March 26, 2026). The code shows no concentrated issuing-body pattern; activity is episodic and does not support a clear forward-pursuit strategy focused on alatrofloxacin itself.